Literature DB >> 17414713

Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo.

Alain J Poncelet1, Jonathan Vercruysse, Alain Saliez, Pierre Gianello.   

Abstract

BACKGROUND: In vitro, mesenchymal stem cells (MSCs) have demonstrated a low immunogenic profile. In this study, we tested the immune response to allogeneic MSCs in immunocompetent swines both in vitro and in vivo.
METHODS: Major histocompatibility complex-controlled swine leukocyte antigen (SLA) and SLA were used as donor and recipient, respectively. In vitro, proliferative responses were tested by mixed lymphocyte reaction (MLR) or cocultures and cytokine profiling by enzyme-linked immunosorbent assay. In vivo, allogeneic MSCs were injected in cardiac infarcted area (n=3) and compared with subcutaneous injections of either MSCs (n=2) or peripheral blood mononuclear cells (PBMCs; n=2). Two additional animals received a skin graft as controls. No immunosuppression was used. Specific antidonor humoral responses were tested by flow cytometry and complement-dependent cytotoxicity assay.
RESULTS: In vitro, either unstimulated MSCs or interferon (IFN)-gamma stimulated MSC failed to elicit a proliferative response (stimulation index: 1.23 vs. 1.12 vs. 36.9 for controls, P<.001). Concomitantly to the absence of proliferation to MSCs, low production of IFN-gamma and interleukin-2 was evidenced in supernatants while the production of Th2 cytokines was comparable to controls. In vivo, all animals receiving skin grafts, subcutaneous PBMCs and intracardiac MSCs injections developed donor-specific cellular and humoral responses (immunoglobulins M and G) with antibody-complement-mediated cytotoxicity. Subcutaneous MSCs injection needed a rechallenge to similarly develop a cytotoxic humoral response.
CONCLUSIONS: Intracardiac allogeneic porcine mesenchymal stem cells elicit an immune response despite their low immunogenic profile in vitro. This result suggests that in vivo characteristics of allogeneic MSCs might differ and emphasizes the importance of pursuing research both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414713     DOI: 10.1097/01.tp.0000258649.23081.a3

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  81 in total

Review 1.  Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.

Authors:  James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

2.  Translational development of mesenchymal stem cell therapy for cardiovascular diseases.

Authors:  Joshua M Hare
Journal:  Tex Heart Inst J       Date:  2009

Review 3.  Immunomodulation by mesenchymal stem cells in veterinary species.

Authors:  Danielle D Carrade; Dori L Borjesson
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

Review 4.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 5.  Death and inflammation following somatic cell transplantation.

Authors:  Ian B Copland; Jacques Galipeau
Journal:  Semin Immunopathol       Date:  2011-05-01       Impact factor: 9.623

Review 6.  Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges.

Authors:  Jörn Tongers; Douglas W Losordo; Ulf Landmesser
Journal:  Eur Heart J       Date:  2011-02-28       Impact factor: 29.983

7.  Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis.

Authors:  Olga DelaRosa; Beatriz Sánchez-Correa; Sara Morgado; Cristina Ramírez; Borja del Río; Ramón Menta; Eleuterio Lombardo; Raquel Tarazona; Javier G Casado
Journal:  Stem Cells Dev       Date:  2011-10-18       Impact factor: 3.272

8.  Stem cell therapy: a potential for the perils of pancreatitis.

Authors:  Harleen Chela; Bhupinder S Romana; Markandeya Madabattula; Abdulmajeed A Albarrak; Mohamad H Yousef; Sami Samiullah; Veysel Tahan
Journal:  Turk J Gastroenterol       Date:  2020-06       Impact factor: 1.852

9.  Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages.

Authors:  Marilena Ciciarello; Roberta Zini; Lara Rossi; Valentina Salvestrini; Davide Ferrari; Rossella Manfredini; Roberto M Lemoli
Journal:  Stem Cells Dev       Date:  2012-12-21       Impact factor: 3.272

10.  Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially.

Authors:  S Jyothi Prasanna; Divya Gopalakrishnan; Shilpa Rani Shankar; Anoop Babu Vasandan
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.